Why the study?
Retroperitoneal sarcoma management is challenging, and while surgery is the main curative option, the roles of chemotherapy and radiotherapy for primary disease remain unclear.
Surgery remains the main therapeutic option for primary retroperitoneal sarcoma, while the role of chemotherapy and radiotherapy in primary disease remains unclear.
Surgery remains the mainstay for primary retroperitoneal sarcoma; leaves open the role of chemotherapy and radiotherapy for prospective trials.
Retroperitoneal sarcomas (RPS) are rare cancers whose management can be challenging due to various presentation patterns, multiple organ involvement, and a high local and distant recurrence rate. Histopathology and prognostic factors analysis are essential to predict the behaviour of the disease and plan the best therapeutic strategy. To date, surgery is still the main therapeutic option that guarantees a chance of cure from the primary disease. While chemotherapy and radiotherapy seem to be good options for controlling metastatic and recurrent irresectable disease, their role in the treatment of primary RPS remains unclear. This literature review aims to provide a comprehensive overview of the multidisciplinary aspects of RPS management in high-volume centres, summarising the diagnostic path, the prognostic factors, and the most suitable therapeutic options.
No takes yet. Share an insight, caveat, or question.
Carbone et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: